Trial Profile

Phase I clinical trial of RNDO-564

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RNDO 564 (Primary)
Indications Bladder cancer
Focus First in man; Therapeutic Use

Most Recent Events

10 Feb 2025 According to a Rondo Therapeutics media release, company plans to initiate a Phase 1/b trial in relapsed/refractory, locally advanced/metastatic bladder cancer by year-end.
25 Nov 2024 New trial record
19 Nov 2024 According to a Rondo Therapeutics media release, RNDO-564 is slated for IND filing in Q3 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com